In clinical trials, CAR-T cell therapies targeting various tumor-associated antigens (TAAs), such as CD19/CD20, C-type lectin-like molecule-1 (CLL-1), CD22, CD133, and CD171, have been assessed [59,60,61,62,63,64]. The gene discussed is CLEC12A; the disease is neoplasm.